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society in general.
Background: Ethical guidelines require that clinical research involving humans offer the potential for
beneﬁt. A number of characteristics can be applied to deﬁne research beneﬁt. Often beneﬁt is categorized
as being either direct or indirect. Indirect beneﬁts can involve collective beneﬁts for society rather than
any beneﬁts to the trial patient or subject. The purpose of this review was to examine which potential
individual and societal beneﬁts were mentioned as being expected in publications from government
experts and which were mentioned in publications describing completed drug development trial results.
Methods: Literature on research beneﬁt was ﬁrst identiﬁed by searching the PubMed database using
several combinations of the key words beneﬁt and clinical research. The search was limited to articles
published in English. A Google search with the same combinations of key words but without any
language limitation was then performed. Additionally, the reference lists of promising articles were
screened for further thematically related articles. Finally, a narrative review was performed of relevant
English- and German-language articles published between 1996 and 2016 to identify which of several
potential beneﬁts were either theoretically expected or which were mentioned in publications on clinical
drug development trial results.
Results: The principal beneﬁts from drug development discussed included 2 main types of beneﬁt,
namely individual beneﬁts for the patients and collective beneﬁts for society. Twenty-one of an overall
total of 26 articles discussing theoretically expected beneﬁts focused on individual patient beneﬁts,
whereas 17 out of 26 articles mentioned collective beneﬁts to society. In these publications, the most
commonly mentioned theoretically expected individual patient beneﬁt was the chance to receive up-to-
date care (38.1%). A general increase in knowledge about health care, treatments, or drugs (70.6%) was
the most commonly mentioned theoretically expected beneﬁt for society. In contrast, all 13 publications
reporting actual beneﬁts of clinical drug development trials focused on personal beneﬁts and only 1 of
these publications also mentioned a societal beneﬁt. The most commonly mentioned individual beneﬁt
was an increased quality of life (53.9%), whereas the only mentioned collective beneﬁt to society was a
general gain of knowledge (100.0%).
Conclusions: Both theoretically expected and actually reported beneﬁts in the majority of the included
publications emphasized the importance of individual patient beneﬁts from drug development rather
than the collective beneﬁts to society in general. The authors of these publications emphasized the right
of each individual patient or subject to look for and expect some personal beneﬁt from participating in a
clinical trial rather than considering societal beneﬁt as a top priority. From an ethical point of view, the
beneﬁts each individual patient receives from his or her participation in a clinical trial might also be seen
as a societal beneﬁt, especially when the drug or device tested, if approved for marketing, would
eventually be made available for other similar patients from the country in which the clinical trial was
conducted.
& 2017 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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The business of doing clinical research involving humans
became increasingly common during the last century. During this
period not only were several relevant regulations and laws
implemented, but the importance of the need to consider the
ethical aspects of this activity also became more evident. This led
to the development of various ethical guidelines by different
government and medical organizations. All of these guidelines
focus on the potential for beneﬁt as a requirement for making
clinical research involving humans ethically acceptable. The
required research beneﬁts can be differentiated by various char-
acteristics and are often categorized into direct or indirect beneﬁts.
Indirect beneﬁts are further divided into collective beneﬁts to
society, either excluding or including beneﬁts to the trial patient or
subject.
Three well-known sets of ethical guidelines that form the basis
for conducting clinical research illustrate how the principle of
beneﬁt has evolved over time.The First Ethical Requirements: The Nuremberg Code
The ﬁrst ethical requirements for drug development in the
area of clinical research were developed after the end of the
Second World War as a result of the Nuremberg War Crimes
Trials—also known as the Doctors Trials. These trials involved
illegal human experiments conducted by doctors serving in
concentration camps during the Second World War on concen-
tration camp prisoners and led to the adoption of the Nurem-
berg Code in 1947. This included a set of 10 ethical principles
required for conducting human experimentation and was the
ﬁrst ofﬁcial document to include beneﬁt as a requirement for
ethical human research. The document states in its second
principle that “the experiment should be such as to yield fruitful
results for the good of society.”1 This statement suggests that the
expected beneﬁt (eg, gaining knowledge about new treatments,
medicinal products, or drugs) is for the whole society, not for the
individual patients.A Second Set of Ethical Requirements: The Declaration of
Helsinki
Expanding on the Nuremberg Code, the World Medical Associ-
ation developed and then released the Declaration of Helsinki in
1964. This Declaration was amended several times during the past
50 years as a result of the progress made in clinical research and
associated new challenges. The current version (dated from 2013)
states in its eighth principle that “the primary purpose of medical
research is to generate new knowledge.”2 This deﬁnition is similar
to the Nuremberg Code statement that the expected beneﬁt of
drug development is to society. However, later versions of the
Declaration also include another type of beneﬁt; that the research
should enable “post-trial access for all participants who still need
an intervention identiﬁed as beneﬁcial in the trial.”2 For the ﬁrst
time the individual beneﬁt to the trial subjects—and even beyond
the end of the clinical trial—was considered as a requirement in an
ofﬁcial ethical research document.A Third Set: The Belmont Report
In 1978 a third ofﬁcial document on ethical requirements for
human research was adopted by The National Commission for theProtection of Human Subjects of Biomedical and Behavioral
Research in the United States. This document is called The Belmont
Report and addresses ethical principles and guidelines for the
protection of human subjects participating in all research. The
second principle of the Belmont Report, which covers the aspect of
beneﬁcence, states that the society should beneﬁt “from the
improvement of knowledge and from the development of novel
medical, psychotherapeutic, and social procedures.”3 “Treating
childhood diseases and fostering healthy development” are given
as examples of societal beneﬁts.3 The application of these princi-
ples requires that “the term beneﬁt is used in the research context
to refer to something of positive value related to health or
welfare.”3
The development of these 3 ethical guidelines resulted in the
operationalization of several additional important ethics guidance
documents such as the Common Rule in the United States and the
Guideline for Good Clinical Practice of the International Confer-
ence on Harmonisation of Technical Requirements for Registration
of Pharmaceuticals for Human Use, which was adopted by the
regulatory bodies of the European Union, the United States, and
Japan. The standard of Good Clinical Practice was incorporated into
law such as in the Regulation EU No. 536/2014 in the European
Union and became obligatory for conducting clinical research. This
produced an important change in the clinical research approval
process. As a result, a clinical trial is only acceptable if the risks and
beneﬁts for the trial patients are balanced.
This review was conducted to identify and compare which
theoretically expected beneﬁts are identiﬁed in articles published
by government experts such as at the US National Institutes of
Health versus those mentioned in selected published clinical drug
development trial report results with respect to the types of
beneﬁt mentioned in these documents and to examine whether
they focused more on beneﬁts to society or to individual patients
or subjects.
Unfortunately, the methods used prohibited any examination of
differences in ethical comments in Western versus non-Western
countries. This question is important given the increasing global-
ization of clinical research activity. As noted by Lang et al,4 “clinical
trials are also being conducted across more diverse countries for
economic reasons” and factors that are “increasing the wait for
lifesaving new interventions,” especially for rare disease and
health events. Unfortunately this is beyond the scope of this
article.Deﬁnition of Beneﬁts
The types of beneﬁts identiﬁed were divided into potential
individual patient beneﬁts from receiving new treatments, medical
devices, or drugs and the general beneﬁts to be potentially gained
by society through knowledge obtained from the research. But the
societal beneﬁt of clinical research does not only consist of gaining
new knowledge of diseases, new treatment methods, drugs, or
medicinal products. The inﬂuence on the health care system was
also considered to be a potential collective societal beneﬁt.
Also, potential beneﬁts to individual patients included both
direct and indirect beneﬁts. Direct beneﬁts included those that
would result from the patient or subject’s use of a new medical
treatment, a new drug, or a new medicinal product. The potential
beneﬁts of such treatment could also include a decrease “in the
severity of symptoms” and thereby an increase in the quality of life
or in survival time. Indirect beneﬁts included those resulting from
the participation in research without receiving any direct beneﬁts;
for example, by being part of a control group. Participants who did
not receive the investigation product were still involved in the
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for proving superiority or noninferiority of a new treatment. They
might receive the beneﬁts later, after the market approval of the
new treatment or product. Generation of the comparative data
needed for a market approval would be impossible without
inclusion of patients who accept the risk of being randomized to
not receive the new investigational treatment or product. In fact
the literature suggests that indirect beneﬁts can also result from
trial participation as a control; for example, “the opportunity to
meet with other people and feel useful and helpful, or greater
access provided to professional care and support” as well as
getting monetary reimbursement for participation. In regard to
the latter it is important to distinguish between payment and
reimbursement. Payment refers to monetary beneﬁts whereby
reimbursement addresses only expenses incurred by participants
as a result of trial participation.
Although “all research is designed to beneﬁt the public,”5 only
“some procedures offer the patient-subject the prospect of direct
beneﬁt.”6 Societal beneﬁt will always exist, whereas individual
beneﬁt may only be possible from participation in clinical research.
None of the beneﬁt types discussed are particularly favored in
the 3 major ethical guidelines (Nuremberg Code, Declaration of
Helsinki, and Belmont Report). Generally, when deciding whether
clinical research is ethical, the “potential clinical beneﬁts to
participants, if any, and the social value of the knowledge”5 are
combined. Not every clinical trial includes an individual beneﬁt for
its participants and unfortunately no “upper limit on the net
research risks to which competent adults may be exposed.”5
Therefore, clinical trials can enroll participants only “as long as
the risks are justiﬁed by the societal value of the research.”5 This
means that given a sufﬁciently important scientiﬁc question, some
net risk to subjects may be justiﬁed,”6 because “the overarching
objective of clinical research is to develop generalizable knowledge
to improve health and/or increase understanding of human
biology,”7 and “subjects who participate are the means to securing
such knowledge.”7 Therefore, it might appear that the societal
beneﬁt of drug development from clinical research take prece-
dence over the individual beneﬁts to the patients or subjects. But
is this reﬂected in publications from governmental experts and
selected published clinical drug development trial reports?Methods
A nonsystematic review of the literature on clinical research
beneﬁts was done according to the Preferred Reporting Items for
Systematic Reviews and Meta-Analysis ﬂow diagram and guidance
set out by the Centre for Reviews and Dissemination.8,9 This
review focused on narratives and does not claim to be complete.
The search strategy
Literature on research beneﬁt was ﬁrst identiﬁed by searching
the PubMed database. Several combinations of key words like
beneﬁt and clinical research or direct beneﬁt and patient and clinical
research as well as indirect beneﬁt and patient and clinical research
were used. Further, synonyms like advantage instead of beneﬁt and
clinical trial or clinical study instead of clinical research were
applied. The thematically most promising search string, which
was ﬁnally used, was the combination of direct beneﬁt and patient
and clinical research. Filters such as full text availability, deﬁnition
of publication date, limited to humans, and articles in English
language were used to reduce the search results. The ﬁnal search
was limited to articles published in English between January 1,
1996, and March 31, 2016. A Google (Mountain View, CA) search
with the same combination of key words was then done. Here,only the most thematically promising articles were chosen. This
search was not limited to only articles in English. The literature
identiﬁed in the PubMed database and the Google search was then
screened by reviewing the titles and abstracts. Articles that were
believed to be appropriate, after excluding duplicates, underwent
full-text review by the author. The content of the appropriate
articles were appraised for which beneﬁts from drug development
were mentioned. Articles that did not include any kind of beneﬁt
from drug development were excluded. Only articles referring to
beneﬁts of drug development were included.
Further, the reference lists of promising articles were screened
to identify additional thematically related articles. Any additional
articles believed to be appropriate were selected and their full text
was evaluated regarding comments on the beneﬁts of drug
development trials.
The ﬁnal review covered publications in English and German
language published between January 1, 1996, and March 31, 2016.
The search strategy as per Centre for Review and Dissemination
Guidance recommended is shown in the Figure 1.8
All articles identiﬁed as suitable for the ﬁnal review were
divided into articles discussing theoretically expected beneﬁts
written by experts and published on governmental sites on one
hand and into publications reporting completed clinical drug
development trial results that included a discussion of study
beneﬁts. A similar analysis of both publication types was done to
check whether the theoretically expected beneﬁts mentioned by
governmental experts were included in publications of clinical
drug development trial results.
Documentation in a data extraction form
The data extracted from both publication types were listed in
two separate data extraction forms, which were of identical
design, containing descriptive details and beneﬁt components
(Table I and the supplementary tables are included in Appendix A).
The author, publication year, as well as the topic of the publication
were documented as were the beneﬁt components divided into
either patient or societal beneﬁt along with a more detailed
description of the beneﬁcial aspects mentioned.
Data classiﬁcation
The beneﬁt components collected in the data extraction forms
were classiﬁed in subcategories after dividing them into the
groups of patient beneﬁts and societal beneﬁts with the frequency
of each beneﬁcial aspect enumerated.
In summary, this narrative review was designed to screen the
selected literature to identify the beneﬁts most frequently men-
tioned expected or actual clinical research beneﬁts and to further
detail these outcomes.Results
Analysis of descriptive data
A total of 39 publications were selected and divided into a
group of articles discussing theoretically expected beneﬁts and a
group of articles reporting actual beneﬁts of a clinical drug
development trial. The group focusing on theoretically expected
beneﬁts included 26 articles, mostly written by experts, from
government sites and 13 articles reporting actual beneﬁts from a
clinical drug development trial were mostly written by authors
from academia. The descriptive data (Tables II and III) contain
author’s name, publication year, and a brief topic description of the
article.
Literature search sources:
PubMed, Google, handmade reference check
Key words: direct benefit, patient, clinical research   
Period: January 1, 1996, until March 31, 2016
Filter: Full text, publication date from January 1, 1996, until 
March 31, 2016, humans, English language
Resultant Articles: 1915
(PubMed: 1894, Google: 8, handmade reference check:13)
Review of title and abstract, duplicate check
Appropriate articles for full text review: 54
Exclusion of irrelevant articles
Articles included in the narrative review: 39
1861 articles were not included into
the full text review due to duplicate 
exclusion, inappropriate content or 
misleading title
15 articles were irrelevant for the 
final review due to a lack of 
appropriate data for the beneficence 
topic or an insufficient discussion of 
this topic
Fig. 1. Preferred reporting items for systematic reviews and meta-analysis ﬂow diagram presenting the search strategy.
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beneﬁt (n ¼14), ethics (n ¼6), effects (n ¼ 3), and clinical research
(n ¼ 8) as well as clinical trial/trial (n ¼ 20) in their titles.
Analysis of beneﬁt data
In the 39 included articles the beneﬁts from drug development
were routinely divided into 2 main classes, namely individual beneﬁts
for the patients or subjects and into collective beneﬁts for society.10 In
12 of the 26 theoretically expected beneﬁt articles both patient
beneﬁts and societal beneﬁts were mentioned. Nine of these 26
publications focused on personal beneﬁts and 5 publications focused
on societal beneﬁts. In total, 21 out of 26 theoretical beneﬁt pub-
lications mentioned personal patient beneﬁts, whereas 17 publications
discussed collective beneﬁts to society. In contrast, only 1 of the 13
actual clinical trial reports included both patient and societal beneﬁts
while the 12 other publications focused only on personal beneﬁts.
Classiﬁcation of beneﬁt data
The data in the extraction forms were used to generate
percentage frequency scales of mentioned patient and societal
beneﬁts per article type. The frequency scale for the theoretically
expected beneﬁts articles included only desired beneﬁts, whereas
the frequency scale for the clinical drug development trial reports
included actual beneﬁts.Table I
Examples from the data extraction form covering descriptive details and beneﬁt compo
Author Year Topic Pati
ben
Lemaire F17 2004 Patient care vs clinical research Yes
Freedberg K18 1995 Effectiveness of prophylaxis for Pneumocystis
carinii pneumonia in patients with AIDS
YesThe most commonly mentioned theoretically expected societal
beneﬁts were the general gain of knowledge about health care,
treatments, or drugs (70.6%). The second most commonly men-
tioned beneﬁts were the subsequent availability of new treat-
ments, technologies, or drugs (29.4%). In 11.8% of these
publications, new facilities or clinics, access to medicines, sustain-
ability, and improvement in health care (11.8%); as well as clean
water, longer life, cost-effectiveness, and employment or training
of medical professionals (5.9%) were additional potential societal
beneﬁts. In contrast to these expectations, only 1 of the 13 actual
clinical trial reports included a collective societal beneﬁt: General
gain of knowledge.
The theoretically expected patient beneﬁts frequency scale is
represented in Table IV. The most commonly mentioned theoret-
ically expected beneﬁt (38.1%) was the chance to receive up-to-date-
care. The second most commonly mentioned beneﬁt was an
increased quality of life (33.3%). Other theoretically expected patient
beneﬁts were access to health care or provision of treatment or
drugs (23.8%), reimbursement for trial-related expenses (23.8%),
altruism (14.3%), improved survival time (14.3%), and longer life
(14.3%). Other beneﬁts mentioned included improvement of health,
knowledge gain, maximization of one’s own health, as well as
posttrial access to drugs (9.5%), symptom reduction, emotional
improvement, contribution to scientiﬁc research, decreased morbid-
ity and mortality, and control of the disease (4.8%).
In contrast to the theoretically expected patient beneﬁts listed














Example from the data extraction form listing descriptive details of articles
discussing theoretically expected beneﬁts.
Author Year Topic
Lemaire F17 2004 Patient care versus clinical research
Freedberg K18 1995 Cost-effectiveness of prophylaxis for Pneumocystis
carinii pneumonia in patients with AIDS
Table IV
Classiﬁcation of theoretically expected patient beneﬁt.
Beneﬁt type %
Up-to-date-care 38.1
Quality of life 33.3





Improvement of health 9.6
Knowledge gain 9.6
Maximization of own outcome / health 9.6
Posttrial access to drug 9.6
Symptom reduction 4.8
Emotional improvement 4.8
Contribution to scientiﬁc research 4.8
Decrease of morbidity / mortality 4.8
Control of the disease 4.8
Hope / trust for cure 0
Cost reduction 0
Meeting other patients 0
Time to progression 0
Closer monitoring 0
Receipt of second opinion 0
Independent handling of future disease 0
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development trial results. Here, the most commonly mentioned
beneﬁt (53.9%) was an increased quality of life. Access to health
care or provision of treatment or drugs was the second most
commonly mentioned beneﬁt (38.5%), followed by the chance to
receive up-to-date care (30.8%). Other important patient beneﬁts
were altruism, hope, and trust for cure as well as cost reduction
(all 23.1%). Symptom reduction, emotional improvement, and
contribution to scientiﬁc research were also mentioned (15.4%).
Reimbursement for trial-related expenses, improved survival time,
longer life, improvement of health, knowledge gain, maximization
of one’s own health, as well as the opportunity to meet other
patients, prolongation of time to progression, closer monitoring,
receipt of a second opinion, and an independent handling of future
disease (all 7.7%) were other beneﬁts mentioned.Table V
Classiﬁcation of actual reported patient beneﬁt.
Beneﬁt type %
Quality of life 53.89
Access to health care / treatment / drug 38.5
Up-to-date-care 30.8
Altruism 23.1




Contribution to scientiﬁc research 15.4
Payment 7.7
Survival 7.7Discussion
By comparing the theoretically expected beneﬁts and the
actually reported beneﬁts, it became apparent that individual
patient beneﬁt from involvement in a drug development trial
was mentioned much more frequently than theoretically required
societal beneﬁts. Consequently, it appears that investigators con-
ducting clinical trials concentrate more on what patients who
participate in a clinical trial can expect to personally gain from
participation rather than on only the collective beneﬁts for society.
Perhaps this is because investigators consider societal beneﬁt to be
automatically an implicit component of participation because
generation of fundamental knowledge about new treatment
methods or drugs will be a natural consequence of all trials.
Furthermore, most if not all clinical research should not be
approved by an institutional review board or ethics committee or
done without aiming to improve the health of at least 1 speciﬁc
population. However, this aim might not always be achieved by
generating fundamental knowledge on diseases, new treatment
methods, or drugs. Sustainable access to new drugs or treatment
methods, as well as new treatment facilities and additional trained
personnel, are potential additional beneﬁts. The theoretically
expected collective beneﬁts for society seem to differ from the
beneﬁts actually reported in most clinical trial results.
Direct patient beneﬁts
In addition to the collective beneﬁts for society, each individual
patient or subject has the right to look for and expect some
personal beneﬁt from participating in a clinical drug developmentTable III
Example from the data extraction form covering descriptive details of articles
listing beneﬁts as reported in publications of completed clinical trial results.
Author Year Topic
Lindenstruth K19 2006 Beneﬁcial effects of soy trial experience
Lindholm-Olinder A20 2015 Effects of acceptance and commitment
therapy in patients with type 1 diabetestrial rather than considering societal beneﬁt as a top priority.11
When comparing the literature from the late 1990s with more
recent literature, it appears that the individual patient beneﬁts
expected from participation in human research have become a
major requirement for a patient or subject’s participation in
clinical drug development trials. It is perhaps not surprising that
20 years ago a general improvement in quality of life was among
the most commonly expected individual beneﬁts for a participant.
Additional fundamental beneﬁts expected include reduction of
symptoms, improved emotional and physical condition, and an
improved prognosis for extended life expectancy. Access to new
treatments or drugs that successfully improve health is also an
expected individual beneﬁt. Such beneﬁts were mentioned in both
theoretical beneﬁts publications as well as in clinical trial reports
and are all direct beneﬁts.Longer life 7.7
Improvement of health 7.7
Knowledge gain 7.7
Maximization of own outcome / health 7.7
Meeting other patients 7.7
Time to progression 7.7
Closer monitoring 7.7
Receipt of second opinion 7.7
Independent handling of future disease 7.7
Posttrial access to drug 0.0
Decrease of morbidity / mortality 0.0
Control of the disease 0.0
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Several indirect beneﬁts, regardless of whether from generation
of comparative data or from positive treatment effects, might also
be expected as a result of a patients’ participation in clinical
research. These might include a feeling of altruism from partic-
ipation in clinical research and assistance in the acquisition of new
research knowledge, especially when participating patients help
discover something useful about their own disease. When this
occurs, participants can gain new courage for their further ﬁght
against the disease. In addition, participants often have the
opportunity to interact with other affected patients in a way that
gives them new strength to deal with their illness.
Reimbursement for costs incurred in study participation,
including travel expenses and loss of work, can also be considered
beneﬁts. However, whether such reimbursement of expenses
should be regarded as an indirect beneﬁt for clinical trial partic-
ipants or not is an ethically very controversial topic. Muthuswamy
et al12 advance the view that reimbursement of expenses is not an
individual beneﬁt because it should include only the reimburse-
ment of actual costs incurred and should not serve as an inappro-
priate incentive for ﬁnancially less-well-off patients to agree to
participation in clinical research. In contrast, Denny et al13 does
not consider such payments as negative as long as they are
“considered fair” for patients. In general any reimbursement of
expenses or payment should be planned transparently in cooper-
ation with the responsible ethics committee or institutional review
board.
Another signiﬁcant theoretical beneﬁt is the expected long-
term access of the participants to any substance, device, or treat-
ment shown to be effective in the clinical trial in which they
participated. However, the clinical drug development trial reports
reviewed here suggest that short-term improvements were more
important for patients compared with any long-term beneﬁts. This
aspect is also an ethically controversial topic. According to Lang
et al4 the “post-trial access to medicines and devices are an
integral part of […] trust between researchers and the commun-
ity.” Trust is always an important aspect of patients’ participation
in clinical research regardless of whether patients might expect
any direct or indirect beneﬁts. However, González-Saldivar et al14
stated that participants assigned to the control group often have
“the perception that study participants are not protected” and
“that in research projects the participant’s health is endangered.”
This suggests that participants who do not receive any of the
previously mentioned expected direct beneﬁts may develop dis-
trust in research. The expectation of receiving long-term beneﬁts
may be particularly important for compliance with the ethical
codices of clinical drug development trials conducted in resource
poor countries. From an ethical point of view, the beneﬁts each
individual patient receives from participation in a clinical trial
might also be seen as a societal beneﬁt, especially when the drug
or device tested, if approved for marketing, would eventually be
made available for other similar patients from the country in
which the clinical trial was conducted.15
Limitations
Limitations of this review should be taken into consideration.
A small number of studies were included in this nonsystematic
review and the analyses were descriptive.Conclusions
The majority of the included publications emphasized the
importance of individual patient beneﬁts rather than collectivebeneﬁts to society, regardless of whether studies reported theo-
retical or actual beneﬁts. Short-term patient beneﬁts such as
access to treatment, alleviation of symptoms, and improvement
of health were emphasized in these studies. However, long-term
beneﬁts, including posttrial and postmarketing access to study
medications, should be considered. Further, as stated by Limaye
et al,16 “the beneﬁts of […] research should be extended post trial
not only to study subjects but to the entire host community.” The
availability of tested substances or methods is especially important
in emerging countries, where the number of clinical trials is
increasing annually. Finally, there is a need for monitoring of
long-term outcomes to ensure that the expected beneﬁts to
individual patients and to society in general are balanced and
realized.Acknowledgment
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